


RESEARCH ARTICLE

Open Access



Is depression a real risk factor for acute myocardial infarction mortality? A retrospective cohort study

Silvia Cocchio¹, Tatjana Baldovin¹, Patrizia Furlan¹, Alessandra Buja¹, Patrizia Casale², Marco Fonzo¹, Vincenzo Baldo^{1*}  and Chiara Bertoncello¹

Abstract

Background: Depression has been associated with a higher risk of cardiovascular events and a higher mortality in patients with one or more comorbidities. This study investigated whether continuative use of antidepressants (ADs), considered as a proxy of a state of depression, prior to acute myocardial infarction (AMI) is associated with a higher mortality afterwards. The outcome to assess was mortality by AD use.

Methods: A retrospective cohort study was conducted in the Veneto Region on hospital discharge records with a primary diagnosis of AMI in 2002–2015. Subsequent deaths were ascertained from mortality records. Drug purchases were used to identify AD users. A descriptive analysis was conducted on patients' demographics and clinical data. Survival after discharge was assessed with a Kaplan-Meier survival analysis and Cox's multiple regression model.

Results: Among 3985 hospital discharge records considered, 349 (8.8%) patients were classified as 'AD users'. The mean AMI-related hospitalization rate was 164.8/100,000 population/year, and declined significantly from 204.9 in 2002 to 130.0 in 2015, but only for AD users (–40.4%). The mean overall follow-up was 4.6 ± 4.1 years. Overall, 523 patients (13.1%) died within 30 days of their AMI. The remainder survived a mean 5.3 ± 4.0 years. After adjusting for potential confounders, use of antidepressants was independently associated with mortality (adj OR = 1.75, 95% CI: 1.40–2.19).

Conclusions: Our findings show that AD users hospitalized for AMI have a worse prognosis in terms of mortality. The use of routinely-available records can prove an efficient way to monitor trends in the state of health of specific subpopulations, enabling the early identification of AMI survivors with a history of antidepressant use.

Keywords: Epidemiology, Acute myocardial infarction, Depression, Survival

Background

Coronary heart disease (CHD) is the leading cause of mortality worldwide, and ranks among the top six causes of morbidity. Depression accounts for a relevant proportion of the global burden of disease, ranking among the top three causes, despite a low impact on mortality. In high-income countries, acute myocardial infarction (AMI) is the CHD carrying the highest mortality and morbidity rates [1–4].

In the USA, the age-adjusted hospitalization rates for CHDs decreased constantly between 2002 and 2013. Detailed data have shown a drop in the hospitalization rates for ST-segment elevation myocardial infarction (STEMI) and a rise in the proportion of hospital admissions for other forms (NSTEMI) in the past decade in both Europe and the United States [5–7].

A retrospective observational registry study conducted in Sweden found that the annual incidence rate and prevalence of depression rose steadily from 1991 to 2010, increasing more rapidly in women than in men [8]. For both genders, the incidence of clinically-relevant depressive symptoms increases with age, especially in

* Correspondence: vincenzo.baldo@unipd.it

¹Department of Cardiac Thoracic Vascular Sciences and Public Health, Public Health Section, University of Padua, Via Loredan, 18, 35121 Padova, Italy
Full list of author information is available at the end of the article



the case of other ongoing comorbidities or institutionalization [9].

Following an episode of AMI, the incidence of depression ranges widely, from 15 to 30%, for major depressive disorder [10–12], and is around 20% for dysthymia (minor depression) or depressive symptoms [13]. Depression has been associated with a higher risk of cardiovascular events and a higher mortality in patients with one or more comorbidities [14]. Depression has been identified as a prognostic risk factor in CHD: the risk of all-cause mortality and the risk of cardiovascular events rise by 22 and 13%, respectively [3, 12]. Another study investigated the impact of depression on mortality after AMI, reporting a mortality risk at one year of 33% in patients previously diagnosed with depression, as opposed to 26% in the others; and at 19 years after the AMI, the mortality risk was 87 and 78%, respectively [15].

The occurrence of depression in patients with CHD substantially increases the likelihood of a worse cardiovascular prognosis [16]. Knowing the time frame of depression in relation to patient outcomes would have important mechanistic and screening implications [17]. Some authors reported that patients with and without a diagnosis of depression prior to their cardiac event had similar survival rates [18]. Others found mortality higher among patients with even mild, clinically insignificant depressive symptoms prior to their AMI than for those with no symptoms of depression [19]. A meta-analysis confirmed that both premorbid and postmorbid depression are of prognostic significance [17].

In the analysis of the fatality rate after hospitalization for AMI, another important factor to take into account is adherence to evidence-based treatment (EBT) for AMI patients after their discharge from hospital. The international guidelines recommend a combined and continuative use of beta-blockers, aspirin/clopidogrel, statins, and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (ACEIs/ARBs) after a myocardial infarction in order to reduce cardiac morbidity and mortality [20].

The objective of this study was to test the hypothesis of an association between a continuative use of antidepressants, as proxy of a state of depression, prior to the onset of AMI and a higher mortality afterwards, controlling for potential confounders.

Methods

A retrospective cohort study was conducted using administrative data routinely collected by the Public Health District in the Province of Rovigo, in the Veneto Region of Italy. At the time of the study, the Public Health District served a population of about 173,000 with an average age of 45.3 years, an old-age

dependency ratio of 193.7%, and a mortality rate of 11.2 per 1000 population.

Sample

Patients were identified in the database on the basis of a linked anonymized personal code. Inclusion criteria were: hospitalization between December 1, 2002 and December 31, 2015, and discharge with a primary diagnosis of AMI, based on the International Classification of Diseases, Ninth Revision [ICD-9-CM] codes 410.xx. Patients were enrolled in the study only once, on their first hospitalization (i.e. they had not been admitted to hospital for AMI during the previous two years). The follow-up started 30 days after discharge and continued until time of death or 31/12/2015.

Data sources and definition

Hospital discharge records, coded according to the ICD-9-CM, were extrapolated for all public and accredited private hospitals in the area. A specific ICD code (410.7x) was assigned to patients with NSTEMI, while other codes were used to define patients with STEMI. Deaths during the follow-up were ascertained from mortality records, coded according to the ICD-9-CM, from the Veneto Cause of Death Register. For residents in the Public Health District of Rovigo the cause of death is coded, reported, and validated on death certificates by personnel at the local health agencies. We grouped the dead in five classes based on the the main cause of death: (i) malignancy (ICD: 140–239); (ii) endocrine diseases (ICD: 240–279); (iii) cardio-circulatory system illness (ICD: 390–459); (iv) respiratory illness (ICD: 460–519); and (v) others (all other ICD) [21].

Drug purchases, based on the Anatomical Therapeutic Chemical classification (ATC), were used to identify “users or non-users of antidepressants” and adherence to therapies.

To classify patients as users or non-users of antidepressants, the purchase of antidepressants was used as a proxy measure of a state of depression. Specifically, according to the ATC codes, the following classes of antidepressants were considered: non-selective monoamine reuptake inhibitors (NSMRIs) (ATC code: N06AA), selective serotonin reuptake inhibitors (SSRIs) (ATC code: N06AB), and other antidepressants (ATC code: N06AX). Patients were considered as users of antidepressants if they took this medication continuously for a period of at least 24 weeks within two years prior to admission for AMI.

As regards EBT for AMI, beta-blockers (ATC code: C07), aspirin /clopidogrel (ATC code: B01A), statins (ATC code: C10) and ACEIs/ARBs (ATC code: C09) were considered. After discharge, for each class of antidepressants and for each class of EBT for AMI, drug adherence was

assessed by means of a medication possession ratio during the follow-up period, i.e. from the day after hospital discharge to the last day of involvement in the study (end of study or patient's death). Specifically, for antidepressants and beta-blockers, statins and ACEIs/ARBs, we calculated the proportion of days on which a patient had the medication available (assuming that one pill a day was necessary), while aspirin/clopidogrel adherence was measured as the ratio of the number of dates on which drugs were prescribed to the number of months in the study. For each medication class, patients were classified as adherent (adherence measure >80%) or nonadherent (otherwise). Patients were considered as adherent to the combined EBT for AMI if they had continuously taken medication from each of the four classes of drugs.

For all patients, comorbidities were identified from all secondary diagnoses in their hospital discharge records and graded according to the Charlson Comorbidity Index (CCI) [22], calculated as the sum of the scores for the severity of each comorbid condition, and then categorized as 0, 1, and 2 or more.

Statistical analysis

A descriptive analysis was conducted on patients' demographics and clinical data. Data were presented as percentages for categorical variables, and compared using the chi-square test or Fisher's exact test, or as means \pm standard deviations (SD), median with interquartile range (IQR) for continuous variables, which were compared using Student's t-test for unpaired data, performing a priori tests for equality of variances. Baseline clinical characteristics were reported by age group as follows: up to 65 years old; from 66 to 80 years old; and 80 or older.

Patient survival after hospital discharge was assessed with a Kaplan-Meier survival analysis. Since it has been amply demonstrated that 30-day mortality is associated with AMI-related mortality, patients who died within 30 days of their AMI were excluded from the cumulative survival analysis. Survival curves were compared using the log-rank and Breslow tests. To examine the association between AD use and the outcomes of interest, we controlled for potential confounders (age, sex, CCI, type of AMI, and adherence to EBT for AMI and to antidepressant therapy after discharge) using a Cox's multiple regression model. To assess the effect of the time variable on the risk of the event, and to overcome the hypothesis of intrinsic proportional risks in Cox's model, the whole follow-up was divided into shorter time intervals, and a variable representing the period in which the event occurred was included in the regression model. A p -value of <0.05 was accepted as statistically significant. The analyses were performed using the Statistical Package for the Social Sciences (SPSS 22.0; SPSS Inc.,

Chicago, USA). Significant trends in the study period of AMI-related hospitalization were assessed as average annual percent changes (AAPC) [23] using the Joinpoint Regression Program (JPR Version 4.7.0.0; Statistical Methodology and Applications Branch, Surveillance Research Program, National Cancer Institute, USA).

Results

During the study period, 3985 patients at their first hospitalization and with a primary diagnosis of AMI were considered. The flow-chart in Fig. 1 summarizes the patient and study group selection process.


Table 1 shows the study population's demographic and baseline clinical characteristics. Overall, of the 3985 patients included in the analysis, 2428 (60.9%) were male. The men were significantly younger than the women (mean 68.2 ± 13.0 versus 78.0 ± 12.0 years, $p < 0.001$). Among the 349 AD users, 48.7% used SSRIs, 20.9% used NSMRIs, and 30.4% used other ADs. The proportion of patients classified as "AD users" was significantly higher for women than for men (13.9% versus 5.4%, respectively, $p < 0.001$).

Overall, considering a CCI of $1 \geq 1$, 49.1% of the hospital discharges (1955) involved patients with at least one comorbidity, with no significant difference between the groups of patients who were and were not AD users, but when a CCI ≥ 2 was considered, this was found significantly more often among the AD users (27.5% versus 21.7%, $p < 0.05$).

During the study period, the mean rate of AMI-related hospitalizations was 164.8 per 100,000 population a year (207.7 per 100,000 males, and 124.7 per 100,000 females). As concerns age, the peak was recorded among adults aged 80 years and over, with an AMI-related hospitalization rate of 8.4 per 1000 population a year. In the period considered, the temporal trend of AMI-related hospitalizations, and the AAPC in particular, showed a gradual and significant reduction from 204.9 in 2002 to 130.0 per 100,000 population in 2015, down 36.6% compared to 2002 [AAPC: $-2.7^{(-3.7; -1.7)}$].

The temporal trends of the AMI-related hospitalization rates in patients stratified by AD users and non-users are shown in Fig. 2. The reduction in AMI-related hospitalizations was entirely attributable to the latter group, which saw a 40.4% reduction from 2002 to 2015 [AAPC: -3.1 (95% CI: $-4.1; -2.1$)], whereas the trend among the AD users rose by 43.4% [AAPC: 2.3 (95% CI: 0.6; 5.2)].

The overall mean follow-up was 4.6 ± 4.1 years, while it was 3.2 ± 3.4 years for the AD users group and 4.7 ± 4.1 years for the other group. Overall, 523 subjects (13.1%) died within 30 days of their AMI, and for 89.3% of them the cause of death was cardiovascular disease.



For the 3449 patients surviving beyond 30 days after their discharge from hospital, the mean survival was 5.3 ± 4.0 years. As shown in Fig. 3, the mean survival was shorter among AD users (4.0 ± 3.4 years) than among non-users (5.4 ± 4.0 years; $p < 0.01$).

During the follow-up, both all-cause mortality and cardiovascular-specific mortality were higher among AD users group than among non-users group ($p < 0.01$) (Table 2).

Regarding their EBT for AMI, adherence was significantly higher - for each class of medication - among patients who were not AD users ($p < 0.05$). The aspirin/clopidogrel class of EBT for AMI was associated with the highest adherence in both groups, irrespective of any use of antidepressants. Considering

the combined EBT for AMI, the overall adherence was 50.8%, and it was specifically 51.5% among not AD users, as opposed to 43.1% in the other group ($p < 0.05$) (Table 3).

After adjusting for potential confounders, the results confirmed that use of all three classes of antidepressants was independently associated with mortality: all ADs (adj OR = 1.75, 95% CI: 1.40–2.19); NMSRs (adj OR = 1.57, 95% CI: 1.10–2.29); SSRIs (adj OR = 1.71, 95% CI: 1.28–2.28); and other ADs (adj OR = 1.96, 95% CI: 1.42–2.72). Mortality was also significantly associated with sex, being higher among males (adj OR = 1.25, 95% CI: 1.12–1.41); age (adj OR = 1.06, 95% CI: 1.05–1.07); and CCI (adj OR = 1.19, 95% CI: 1.16–1.22). Adherence to combined EBT for AMI had a protective role (adj OR = 0.76, 95% CI:

Table 1 Characteristics of 3985 patients hospitalized for AMI and stratified by AD use

Variables	Antidepressant use		<i>p</i> value
	Yes (n. 349)	No (n. 3636)	
Gender [n(%)]			
Males	132 (5.4)	2296 (94.6)	
Females	217 (13.9)	1340 (86.1)	$p < 0.05$
Age [mean \pm (SD)]	76.1 (11.7)	71.6 (13.6)	$p < 0.05$
Follow-up in years [median \pm (IQR)]	2.0 (0.2–5.2)	3.8 (0.8–7.7)	$p < 0.05$
Length of stay in days [median \pm (IQR)]	10.0 (7.0–16.0)	10.0 (7.0–14.0)	$p = 0.07$
Charlson comorbidity index [n (%)]			
0	162 (8.0)	1868 (92.0)	
1	91 (8.5)	978 (91.5)	$p = 0.60$
≥ 2	96 (10.8)	790 (89.2)	$p < 0.05$
Acute myocardial infarction [n(%)]			
STEMI	199 (8.8)	2066 (91.2)	
NSTEMI	150 (8.7)	1570 (91.3)	$p = 0.94$

SD standard deviation, IQR interquartile range, STEMI ST-segment elevation myocardial infarction, NSTEMI non-ST-segment elevation myocardial infarction




Fig. 2 AMI-related hospitalization rate (per 100,000 population) by antidepressant use (2002–2015)

0.73–0.80), while adherence to antidepressant treatment after discharge was irrelevant.

Discussion

In our study, the AMI-related hospitalization rate decreased constantly during the period investigated, while among AD users the rate of hospitalization for AMI remained steady. A similar trend has been observed in other high-income countries, presumably due to a marked improvement in the treatment of CHDs in recent decades [24]. The steady rate of AMI-related hospitalization involving AD users could be explained by

an improvement in the monitoring of antidepressant medication over the study period too, which may enable a better definition of depressive status.

The AMI-related hospitalization rate in our study was higher for men than for women; and males were younger than females on average. These results are consistent with the literature, which has drawn attention to gender-related differences in the occurrence of AMI [25–27].

About 9% of the patients in our sample had a history of antidepressant use, and they had a higher mortality after AMI than patients without this condition. Depressive




Fig. 3 Survival analysis comparing AD users versus non-users

Table 2 Distribution of 1322 patients who died, by antidepressant use and cause of death

Cause of death	Antidepressant use				Total (n. 3449)	
	Yes (n. 281)		No (n. 3168)		n	(%)
	n	(%)	n	(%)		
Cardiovascular system illness	96	(34.2)	760	(24.0)	856	(24.8)
Malignancy	9	(3.2)	175	(5.5)	184	(5.3)
Endocrine diseases	3	(1.1)	63	(2.0)	66	(1.9)
Respiratory illness	4	(1.4)	49	(1.5)	53	(1.5)
Others	29	(10.3)	134	(4.2)	163	(4.7)
All deaths	141	(50.2)	1181	(37.3)	1322	(38.3)

Denominator of percentage is the number of patients surviving beyond 30 days after their discharge from hospital (in the column)

disorders are common among people suffering from cardiovascular diseases and are associated with a broad range of adverse outcomes. In patients with AMI, depressive symptoms have emerged as a prognostic risk factor for a higher cardiovascular-specific mortality, recurrent hospital admissions, worse general health and well-being, and higher costs of care, even in the absence of a clinical diagnosis of depression [28, 29]. The women in our sample were more likely to use antidepressants before being hospitalized for AMI. This finding is consistent with a multicenter study conducted in Canada, the USA and Switzerland, in which data were collected on patients aged 18–55 years using a self-report questionnaire that included a validated standard tool for assessing depression [30–33].

Regarding the association between antidepressant use and the risk of CHD among subjects with no history of CHD, the results of a meta-analysis provide no evidence of any association between SSRI or NSMRI use and CHD risk [34]. Although the use of antidepressants in patients with CHD helps to control their depression, their use in this group is controversial. The results of a meta-analysis nonetheless found that SSRI use in these patients reduces their depression symptoms and may improve their CHD prognosis [16].

Patients hospitalized with AMI are at particularly high risk of mortality, but the mortality rates for patients

hospitalized with heart failure can vary significantly, ranging from 5 to 9% [35]. The prognosis after hospitalization for AMI is also reportedly very poor, with a 10-year mortality risk of 48.6% [36]. The 30-day mortality rate of 13.1% seen in our sample could be due to the patients' advanced age, and associated chronic conditions. In fact, the sample's long-term survival was consistent with other published reports.

The association seen between chronic physical conditions and depression is common. Depression has been associated with a higher incidence of at least one chronic comorbidity, while people with chronic diseases have been found more prone to suffer from depression than people in good health [37, 38]. Our study identified a better survival rate for patients hospitalized for AMI with no history of antidepressant treatment. This difference, was confirmed even after adjusting for age, gender, CCI, adherence to EBT for AMI, and type of AMI. Depression in patients who experience AMI remains a severe condition and warrants treatment and care. Patients with a history of moderate-severe depressive symptoms may benefit from adequate treatment, or at least careful clinical follow-up, after they have been hospitalized for AMI, in order to monitor any rapid mood swings and start treatment should symptoms persist.

Patients with depression are less likely to adopt an adequately healthy lifestyle in order to reduce their cardiac risk after an AMI [39], and nonadherence to medication is significantly higher among the depressed [40]. Focusing on the evidence-based treatment as a whole, the proportions of patients adhering to the combined EBT for AMI were much the same as in other studies, and our findings confirm the positive effects of EBT for AMI on survival after AMI [20].

Our results show that it is important to identify AMI patients at high risk of depression, so that they can be targeted for depression screening, and benefit from appropriate treatment in relation to their baseline conditions [18]. In our study, there was no difference in mortality between patients who were or were not given continuative antidepressants after discharge. This finding

Table 3 Adherence to AMI evidence-based treatment in the follow-up of 3449 patients

EBT class	Antidepressant use				Total (n. 3449)	
	Yes (n. 281)		No (n. 3168)		n	(%)
	n	(%)	n	(%)		
Aspirin/Clopidogrel	242	(86.1)	2879	(90.9)	3121	(90.5)
Beta-blockers	185	(65.8)	2308	(72.9)	2493	(72.3)
Statins	176	(62.6)	2293	(72.4)	2469	(71.6)
ACEIs/ARBs	184	(65.5)	2344	(74.0)	2528	(73.3)
Combination EBT	121	(43.1)	1630	(51.5)	1751	(50.8)

EBT evidence-based treatment, ACEIs angiotensin-converting enzyme inhibitors, ARBs angiotensin receptor blockers

is consistent with another study that examined the timing of antidepressant prescription vis-à-vis the time of hospital discharge after AMI [19]. It is still by no means clear whether managing any depression can improve survival after AMI, and clinical trials on this issue are obviously needed, also to ascertain the most appropriate treatment for post-AMI depression. Currently-available evidence nonetheless indicates that psychotherapy and psychoactive pharmacological treatments are both safe and effective in reducing depression in patients with cardiovascular diseases [41].

A limitation of our study lies in that patients were identified as AD users (considered as a proxy for a state of depression) on the basis of their having purchased antidepressants for more than 24 consecutive weeks prior to their hospitalization for AMI, not on the grounds of a clinical diagnosis. The threshold of 24 weeks has been adopted by several clinical practice guidelines as an indication of treatment for chronically depressed patients, however [42]. A clinical assessment of the severity of AMI was also lacking in our study. The main strength of our study, on the other hand, concerns the AMI population analyzed, which was numerically large, well defined, and followed up for several years after discharge from hospital.

Conclusions

Our findings show that AD users hospitalized for AMI have a worse prognosis in terms of mortality. The use of routinely-available records can prove an efficient way to monitor trends in the state of health of specific subpopulations, enabling the early identification of AMI survivors with a history of depression.

Abbreviations

AAPC: Average annual percent changes; ACEIs: Angiotensin-converting enzyme inhibitors; ADs: Antidepressants; AMI: Acute myocardial infarction; APC: Annual percent change; ARBs: Angiotensin receptor blockers; ATC: Anatomical therapeutic chemical classification system; CCI: Charlson Comorbidity Index; CHD: Coronary heart disease; EBT: Evidence-based treatment; ICD-9-CM: International Classification of Diseases, Ninth Revision; IQR: Interquartile range; NSMRIs: Non-selective monoamine reuptake inhibitors; NSTEMI: Non-ST-segment elevation myocardial infarction; SSRIs: Selective serotonin reuptake inhibitors; STEMI: ST-segment elevation myocardial infarction

Acknowledgements

Not applicable.

Funding

The study described in this paper was partially supported by a University grant.

Availability of data and materials

All relevant data are within the paper. Requests for additional information should be addressed to the corresponding author and data may be provided on reasonable request.

Authors' contributions

SC: study conception and design, drafting of the manuscript; TB: study conception, supervision; AB: statistical analyses, data interpretation and

supervision; PC: data interpretation and supervision; PF: statistical analyses, drafting of the manuscript; MF: study conception and design, data collection. VB: study conception, design, supervision and drafting of the manuscript; CB: intellectual content, drafting of the manuscript. All authors have read and approved the final manuscript.

Ethics approval and consent to participate

Data were treated with full confidentiality in accordance with Italian legislation. Before the database was made available to the authors, patient identifiers were replaced with anonymous codes that make it impossible to identify the individuals concerned. It was unnecessary to obtain patients' informed consent, given the anonymous nature of the data and its mandatory recording (anonymized data may be analyzed and used in aggregate form for scientific studies without further authorization) [43]. This study complies with the Declaration of Helsinki.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

¹Department of Cardiac Thoracic Vascular Sciences and Public Health, Public Health Section, University of Padua, Via Loredan, 18, 35121 Padua, Italy.

²Public Health Unit "Polesana", Rovigo, Veneto Region, Italy.

Received: 6 November 2018 Accepted: 10 April 2019

Published online: 24 April 2019

References

- WHO | The global burden of disease: 2004 update [Internet]. WHO. [cited 2018 Feb 21]. Available from: https://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf?ua=1
- WHO | The top 10 causes of death [Internet]. WHO. [cited 2018 Feb 21]. Available from: <http://www.who.int/mediacentre/factsheets/fs310/en/>
- Nicholson A, Kuper H, Hemingway H. Depression as an aetiological and prognostic factor in coronary heart disease: a meta-analysis of 6362 events among 146 538 participants in 54 observational studies. *Eur Heart J*. 2006 Dec;27(23):2763–74.
- Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: global burden of disease study. *Lancet Lond Engl*. 1997;349(9063):1436–42.
- Ziaeian B, Kominski GF, Ong MK, Mays VM, Brook RH, Fonarow GC. National Differences in trends for heart failure hospitalizations by sex and race/ethnicity. *Circ Cardiovasc Qual Outcomes*. 2017;10(7). <https://doi.org/10.1161/CIRCOUTCOMES.116.003552>
- Khera S, Kolte D, Aronow WS, Palaniswamy C, Subramanian KS, Hashim T, et al. Non-ST-elevation myocardial infarction in the United States: contemporary trends in incidence, utilization of the early invasive strategy, and in-hospital outcomes. *J Am Heart Assoc*. 2014;3(4). <https://doi.org/10.1161/JAHA.114.000995>
- Rogers WJ, Frederick PD, Stoehr E, Canto JG, Ornato JP, Gibson CM, et al. Trends in presenting characteristics and hospital mortality among patients with ST elevation and non-ST elevation myocardial infarction in the National Registry of myocardial infarction from 1990 to 2006. *Am Heart J*. 2008;156(6):1026–34.
- Carlborg A, Ferntoft L, Thureson M, Bodegard J. Population study of disease burden, management, and treatment of bipolar disorder in Sweden: a retrospective observational registry study. *Bipolar Disord*. 2015;17(1):76–85.
- Depression: practice essentials, background, pathophysiology [internet]. [cited 2018 Feb 21]. Available from: <http://www.staff.science.uu.nl/~ooste108/ExpC/website2/v3/depressionOverview.html>
- Strik JJ, Honig A, Lousberg R, Denollet J. Sensitivity and specificity of observer and self-report questionnaires in major and minor depression following myocardial infarction. *Psychosomatics*. 2001;42(5):423–8.

11. Strik JJMH, Lousberg R, Cheriex EC, Honig A. One year cumulative incidence of depression following myocardial infarction and impact on cardiac outcome. *J Psychosom Res.* 2004;56(1):59–66.
12. Meijer A, Conradi HJ, Bos EH, Anselmino M, Carney RM, Denollet J, et al. Adjusted prognostic association of depression following myocardial infarction with mortality and cardiovascular events: individual patient data meta-analysis. *Br J Psychiatry J Ment Sci.* 2013;203(2):90–102.
13. Thombs BD, Bass EB, Ford DE, Stewart KJ, Tsilidis KK, Patel U, et al. Prevalence of depression in survivors of acute myocardial infarction. *J Gen Intern Med.* 2006;21(1):30–8.
14. Martin-Subero M, Kroenke K, Diez-Quevedo C, Rangil T, de Antonio M, Morillas RM, et al. Depression as measured by PHQ-9 versus clinical diagnosis as an independent predictor of long-term mortality in a prospective cohort of medical inpatients. *Psychosom Med.* 2017;79(3):273–82.
15. Sundbøll J, Schmidt M, Adelborg K, Pedersen L, Bøtker HE, Videbech P, et al. Impact of pre-admission depression on mortality following myocardial infarction. *Br J Psychiatry J Ment Sci.* 2017;210(5):356–61.
16. Pizzi C, Rutjes AWS, Costa GM, Fontana F, Mezzetti A, Manzoli L. Meta-analysis of selective serotonin reuptake inhibitors in patients with depression and coronary heart disease. *Am J Cardiol.* 2011;107(7):972–9.
17. Leung YW, Flora DB, Gravelly S, Irvine J, Carney RM, Grace SL. The impact of premyocardial infarction and postmyocardial infarction depression onset on mortality and cardiac morbidity among patients with coronary heart disease: meta-analysis. *Psychosom Med.* 2012;74(8):786–801.
18. Dickens C, McGowan L, Percival C, Tomenson B, Cotter L, Heagerty A, et al. Depression is a risk factor for mortality after myocardial infarction: fact or artifact? *J Am Coll Cardiol.* 2007;49(18):1834–40.
19. Bush DE, Ziegelstein RC, Tayback M, Richter D, Stevens S, Zahalsky H, et al. Even minimal symptoms of depression increase mortality risk after acute myocardial infarction. *Am J Cardiol.* 2001;88(4):337–41.
20. Tuppin P, Neumann A, Danchin N, de Peretti C, Weill A, Ricordeau P, et al. Evidence-based pharmacotherapy after myocardial infarction in France: adherence-associated factors and relationship with 30-month mortality and rehospitalization. *Arch Cardiovasc Dis.* 2010;103(6–7):363–75.
21. Baldo V, Cocchio S, Gallo T, Furlan P, Romor P, Bertocello C, et al. Pneumococcal conjugated vaccine reduces the high mortality for community-acquired pneumonia in the elderly: an Italian regional experience. *Bueno V, editor. PLoS One* 2016;11(11):e0166637.
22. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis.* 1987;40(5):373–83.
23. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. *Stat Med.* 2000;19(3):335–51.
24. Jennings SM, Bennett K, Lonergan M, Shelley E. Trends in hospitalisation for acute myocardial infarction in Ireland, 1997–2008. *Heart Br Card Soc.* 2012; 98(17):1285–9.
25. Goldberg RJ, Gorak EJ, Yarzebski J, Hosmer DW, Dalen P, Gore JM, et al. A communitywide perspective of sex differences and temporal trends in the incidence and survival rates after acute myocardial infarction and out-of-hospital deaths caused by coronary heart disease. *Circulation.* 1993;87(6): 1947–53.
26. Yang H-Y, Huang J-H, Hsu C-Y, Chen Y-J. Gender differences and the trend in the acute myocardial infarction: a 10-year nationwide population-based analysis. *ScientificWorldJournal.* 2012;2012:184075.
27. MacIntyre K, Stewart S, Capewell S, Chalmers JW, Pell JP, Boyd J, et al. Gender and survival: a population-based study of 201,114 men and women following a first acute myocardial infarction. *J Am Coll Cardiol.* 2001;38(3): 729–35.
28. Frasure-Smith N, Lespérance F, Talajic M. Depression following myocardial infarction. Impact on 6-month survival. *JAMA.* 1993;270(15):1819–25.
29. van Melle JP, de Jonge P, Spijkerman TA, Tijssen JGP, Ormel J, van Veldhuisen DJ, et al. Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis. *Psychosom Med.* 2004;66(6):814–22.
30. Graham G. Acute coronary syndromes in women: recent treatment trends and outcomes. *Clin Med Insights Cardiol.* 2016;10:1–10.
31. Pilote L, Karp I. GENESIS-PRAXY (GENdEr and sex detErminantS of cardiovascular disease: from bench to beyond-premature acute coronary SYndrome). *Am Heart J.* 2012;163(5):741–746.e2.
32. Albert PR. Why is depression more prevalent in women? *J Psychiatry Neurosci JPN.* 2015;40(4):219–21.
33. Mallik S, Spertus JA, Reid KJ, Krumholz HM, Rumsfeld JS, Weintraub WS, et al. Depressive symptoms after acute myocardial infarction: evidence for highest rates in younger women. *Arch Intern Med.* 2006;166(8):876–83.
34. Grace SL, Medina-Inojosa JR, Thomas RJ, Krause H, Vickers-Douglas KS, Palmer BA, et al. Antidepressant use by class: association with major adverse cardiac events in patients with coronary artery disease. *Psychother Psychosom.* 2018;87(2):85–94.
35. Steg PG, Goldberg RJ, Gore JM, Fox KAA, Eagle KA, Flather MD, et al. Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the global registry of acute coronary events (GRACE)**further information about the project, along with a complete list of the study participants, can be found at www.outcomes.org/grace. *Am J Cardiol.* 2002;90(4):358–63.
36. Plakht Y, Gilutz H, Shiyovich A. Excess long-term mortality among hospital survivors of acute myocardial infarction. Soroka acute myocardial infarction (SAMI) project. *Public Health.* 2017;143:25–36.
37. Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B. Depression, chronic diseases, and decrements in health: results from the world health surveys. *Lancet Lond Engl.* 2007;370(9590):851–8.
38. Satyanarayana S, Enns MW, Cox BJ, Sareen J. Prevalence and correlates of chronic depression in the Canadian community health survey: mental health and well-being. *Can J Psychiatry Rev Can Psychiatr.* 2009;54(6):389–98.
39. Ziegelstein RC, Fauerbach JA, Stevens SS, Romanelli J, Richter DP, Bush DE. Patients with depression are less likely to follow recommendations to reduce cardiac risk during recovery from a myocardial infarction. *Arch Intern Med.* 2000;160(12):1818–23.
40. Kop WJ, Synowski SJ, Gottlieb SS. Depression in heart failure: biobehavioral mechanisms. *Heart Fail Clin.* 2011;7(1):23–38.
41. Rustad JK, Stern TA, Hebert KA, Musselman DL. Diagnosis and treatment of depression in patients with congestive heart failure: a review of the literature. *Prim Care Companion CNS Disord.* 2013;15(4). <https://doi.org/10.4088/PCC.13r01511>
42. Pfennig A, Bschor T, Falkai P, Bauer M. The diagnosis and treatment of bipolar disorder. *Dtsch Arztebl Int.* 2013;110(6):92–100.
43. Garante per la protezione dei dati personali. Autorizzazione generale al trattamento dei dati personali effettuato per scopi di ricerca scientifica. *Gazzetta Ufficiale Della Repubblica Italiana.* 2012 Mar;1(72):47–52.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more [biomedcentral.com/submissions](https://www.biomedcentral.com/submissions)

